Insider Selling: Incyte Co. (NASDAQ:INCY) EVP Sells 2,500 Shares of Stock

Incyte Co. (NASDAQ:INCY) EVP Paula J. Swain sold 2,500 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $86.46, for a total transaction of $216,150.00. Following the transaction, the executive vice president now owns 44,112 shares in the company, valued at approximately $3,813,923.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

NASDAQ INCY traded up $0.45 on Tuesday, reaching $87.94. The company’s stock had a trading volume of 1,174,900 shares, compared to its average volume of 1,268,087. The firm has a market cap of $18.67 billion, a PE ratio of 107.24, a price-to-earnings-growth ratio of 1.26 and a beta of 0.99. The business has a 50-day moving average price of $79.92 and a 200 day moving average price of $80.75. Incyte Co. has a 52 week low of $57.00 and a 52 week high of $89.30. The company has a current ratio of 5.02, a quick ratio of 5.01 and a debt-to-equity ratio of 0.02.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.27. The business had revenue of $551.58 million for the quarter, compared to analysts’ expectations of $534.73 million. Incyte had a net margin of 19.21% and a return on equity of 20.07%. The firm’s revenue for the quarter was up 22.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.41 earnings per share. Analysts anticipate that Incyte Co. will post 2.14 earnings per share for the current fiscal year.

Several research analysts have recently issued reports on INCY shares. Morgan Stanley boosted their price objective on shares of Incyte from $82.00 to $87.00 and gave the stock an “equal weight” rating in a report on Thursday, September 5th. BidaskClub upgraded shares of Incyte from a “sell” rating to a “hold” rating in a report on Thursday, October 10th. JMP Securities boosted their price objective on shares of Incyte from $107.00 to $110.00 and gave the stock a “market outperform” rating in a report on Monday, September 30th. Nomura boosted their price objective on shares of Incyte from $100.00 to $111.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Finally, Cowen restated a “buy” rating on shares of Incyte in a report on Friday, September 27th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Incyte has a consensus rating of “Buy” and a consensus target price of $92.90.

A number of hedge funds and other institutional investors have recently bought and sold shares of INCY. Commonwealth Bank of Australia grew its stake in Incyte by 49.2% during the second quarter. Commonwealth Bank of Australia now owns 376 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 124 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in Incyte by 1.2% during the third quarter. Janney Montgomery Scott LLC now owns 10,254 shares of the biopharmaceutical company’s stock worth $761,000 after buying an additional 126 shares during the last quarter. Securian Asset Management Inc grew its stake in Incyte by 0.7% during the second quarter. Securian Asset Management Inc now owns 18,419 shares of the biopharmaceutical company’s stock worth $1,565,000 after buying an additional 133 shares during the last quarter. LS Investment Advisors LLC grew its stake in Incyte by 2.7% during the third quarter. LS Investment Advisors LLC now owns 6,504 shares of the biopharmaceutical company’s stock worth $483,000 after buying an additional 172 shares during the last quarter. Finally, World Asset Management Inc grew its stake in Incyte by 1.5% during the second quarter. World Asset Management Inc now owns 11,545 shares of the biopharmaceutical company’s stock worth $981,000 after buying an additional 174 shares during the last quarter. 92.27% of the stock is currently owned by institutional investors and hedge funds.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Recommended Story: What is the Hang Seng index?  

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.